With the improved treatment of hepatitis C and the obesity epidemic, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are projected to be the most common cause of liver failure, cirrhosis and transplant in the future. This webinar examines the symptoms, diagnosis, incidence, treatment and mortality implications of NAFLD and NASH.
Life underwriters and medical directors
Nonalcoholic fatty liver disease (NAFLD) is the build up of extra fat in liver cells that is not caused by alcohol. Nonalcoholic steatohepatitis (NASH), a more severe form of NAFLD, causes scarring and inflammation that can lead to liver cirrhosis, cancer and death. National Institutes of Health estimate as many as 30 million people have NASH, which is set to outpace hepatitis C as the primary cause of liver transplantation in the US in the next few years. Not only is incidence rising, but the ages of patients with the disease are getting younger, including pediatrics and teens.